Welcome to our dedicated page for Biostem Tech news (Ticker: BSEM), a resource for investors and traders seeking the latest updates and insights on Biostem Tech stock.
BioStem Technologies, Inc. (OTC: BSEM) generates news that reflects its role as a MedTech company focused on placental-derived allografts for advanced wound care and regenerative therapies. Coverage of BSEM often centers on clinical trial milestones, reimbursement developments, financial reporting, and operational updates related to its BioRetain®-processed product portfolio, which includes brands such as AmnioWrap2™, VENDAJE®, VENDAJE AC®, VENDAJE OPTIC®, American Amnion™, and American Amnion AC™.
Investors and healthcare professionals following BSEM news can expect updates on randomized controlled trials and other clinical studies evaluating BioRetain-preserved placental allografts in chronic wound indications like diabetic foot ulcers and venous leg ulcers. The company has reported top-line clinical results from a multicenter randomized controlled trial in non-healing diabetic foot ulcers, as well as comparative studies versus standard of care and competitor products, and these types of announcements are key components of its news flow.
Another major theme in BioStem’s news is reimbursement and policy. The company regularly comments on Centers for Medicare & Medicaid Services (CMS) rules and Local Coverage Determinations affecting skin substitutes and cellular and tissue-based products. News items have addressed the placement of VENDAJE and VENDAJE AC in a “12-Month Status Quo” category under certain LCDs, the withdrawal of specific LCDs, and the inclusion of these products on Florida Medicaid’s list of covered skin substitutes, along with coverage in multiple state Medicaid programs.
Financial and corporate developments also feature prominently. BioStem has issued press releases on quarterly financial results, restated financial statements related to the treatment of bona fide services fees in a distribution agreement, and the appointment of a new independent registered public accounting firm. Operational news has included the purchase of land in the Research Park at Florida Atlantic University in Boca Raton, Florida, for a future headquarters, as well as partnerships to serve the U.S. Department of Veterans Affairs and community initiatives supporting veterans.
By monitoring this news page, readers can follow BioStem’s clinical evidence generation, reimbursement positioning, financial reporting, and strategic initiatives as they relate to its placental-derived advanced wound care products and BioRetain processing technology.
BioStem Technologies (OTC: BSEM) announced management will present at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026 at 8:45 am ET.
Live and archived webcasts will be available on the company’s investors page at ir.biostemtechnologies.com for interested parties and investors.
BioStem Technologies (OTC: BSEM) announced it filed audited consolidated financial statements for the fiscal years ended December 31, 2024 and 2025 on March 30, 2026. The company said publication of audited statements, plus new finance leadership, advances its goal of a Nasdaq uplisting.
BioStem named a new CFO, auditor and audit committee chair and said these steps strengthen financial reporting processes and support corporate initiatives including a potential Nasdaq listing to increase visibility and liquidity.
BioStem Technologies (OTC: BSEM) reported Q4 2025 net revenue of $10.1 million and full-year 2025 revenue of $47.5 million, with Q4 gross margin of 97% and full-year gross margin of 94%. GAAP net loss was ($11.3 million) in Q4 and ($6.6 million) for 2025.
The company completed the BioTissue surgical and wound asset acquisition on Jan 21, 2026, integrated ~20 direct reps plus 30+ agents, and reported cash equivalents of $29.5 million at Dec 31, 2025 (post-close cash ~$16 million).
BioStem Technologies (OTC: BSEM) appointed Jodi Ungrodt to its Board of Directors and named her Audit Committee Chair, effective March 18, 2026. Ungrodt brings 29 years of life‑sciences accounting leadership and is qualified as a financial expert under SEC, NYSE, and NASDAQ rules.
Her experience includes advising 30+ IPOs, serving more than 70 life‑sciences clients at Ernst & Young, and prior audit committee leadership; she will oversee financial reporting, internal controls and risk management as BioStem pursues public‑market visibility in 2026.
BioStem Technologies (OTC: BSEM) will release its fourth quarter and full year 2025 financial results on March 24, 2026 and host a conference call and webcast at 4:30 PM ET.
Presenters include CEO Jason Matuszewski and CFO Brandon Poe. Registration and webcast access are available via the company's provided links and phone numbers.
BioStem Technologies (OTC: BSEM) announced management will present at the 46th Annual TD Cowen Healthcare Conference on Monday, March 2, 2026 at 3:50 pm ET in Boston, MA.
Interested parties can access live and archived webcasts via the company's investors website at ir.biostemtechnologies.com.
BioStem Technologies (OTC: BSEM) highlighted recent U.S. FDA leadership remarks endorsing expanded use of Bayesian statistical methods in clinical trials and tied that openness to its published randomized controlled trial using Bayesian regression and hurdle modeling.
The company said its DFU study showed superior clinical outcomes for BioRetain® processed allografts, with the BR-AC arm almost twice as likely to achieve lasting wound closure versus standard of care. BioStem plans to apply similar Bayesian analyses to ongoing VLU and DFU studies and cited its BioRetain and CryoTek technologies in preserving tissue integrity.
BioTissue (NASDAQ: BESM) completed the sale of its non-ocular Surgical and Wound Care business to BioStem (OTC: BSEM) on Jan 21, 2026. BioStem acquired exclusive rights to the Neox and Clarix product lines, and BioTissue's Surgical sales team and key support staff will join BioStem's commercial organization. BioTissue will continue manufacturing those products for BioStem while refocusing its commercial strategy on ocular therapies, including Prokera, CAM360 AmnioGraft, AmnioGraft, and AmnioGuard. Management frames the divestiture as a move to concentrate resources on eye care innovation and professional education.
BioStem Technologies (OTC: BSEM) closed an asset purchase of BioTissue Holdings' surgical and wound care business, acquiring the Neox and Clarix product lines plus a nationwide sales force and assigned GPO contracts to expand hospital inpatient and outpatient reach.
Deal consideration is an upfront cash payment of approximately $15 million, plus up to $10 million in regulatory milestone payments for 510(k) clearance and up to $15 million in commercial royalty milestones. The acquired assets generated ~$29 million in sales in 2025 and are expected to contribute positive EBITDA to BioStem in 2026. Post-closing cash and restricted cash is approximately $16 million. Barry Hassett was promoted to Chief Commercial Officer. A conference call is scheduled for Jan 22, 2026 at 8:00am ET.
BioStem Technologies (OTC: BSEM) commented on CMS's withdrawal of all seven proposed Local Coverage Determinations for skin substitutes used to treat diabetic foot ulcers and venous leg ulcers, which would have taken effect on January 1, 2026. The company said the withdrawal ensures continued patient access to VENDAJE and VENDAJE AC and is not expected to impact its ability to serve patients and clinicians. BioStem emphasized its commitment to an evidence-based strategy and to investing in expanded clinical data to demonstrate differentiated performance versus alternatives.